CM 110
Alternative Names: CM-110Latest Information Update: 09 Oct 2023
At a glance
- Originator Guangzhou Excelmab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Small cell lung cancer
Most Recent Events
- 20 Sep 2023 Guangzhou ExcelMab announces intention to submit IND application for Small cell lung cancer in USA and China, in 2025 (Guangzhou ExcelMab pipeline, September 2023)
- 20 Sep 2023 Guangzhou ExcelMab plans a phase I trial of CM 110 for Small cell lung cancer in USA and China, in 2026 (Guangzhou ExcelMab pipeline, September 2023)